Clinical Trials Logo

Carcinoma Prostate clinical trials

View clinical trials related to Carcinoma Prostate.

Filter by:
  • None
  • Page 1

NCT ID: NCT05265988 Recruiting - Carcinoma Prostate Clinical Trials

Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib

MERIDIAN
Start date: October 29, 2021
Phase: Phase 2
Study type: Interventional

Multiparametric assesment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study

NCT ID: NCT04985357 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Start date: June 2024
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

NCT ID: NCT03323879 Terminated - Carcinoma Prostate Clinical Trials

Combined LDR Boost and HDR Whole Gland

Delight
Start date: October 30, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a dose finding Phase I/II study of combined focused LDR brachytherapy boost with whole gland single fraction HDR for men with low and intermediate risk prostate cancer and Dominant Intraprostatic Lesion (DIL) visible on multi parametric MRI. Patients will receive 19 Gy HDR to the whole gland with concurrent LDR brachytherapy boost to the DIL, in a sequential dose escalation manner. Primary endpoints are early toxicity.

NCT ID: NCT03103724 Completed - Carcinoma Prostate Clinical Trials

A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.

EXCALIBUR
Start date: March 16, 2017
Phase: Phase 2
Study type: Interventional

Open label, single arm, phase II multicentre study designed to determine the clinical benefit, as measured by 3-months disease control rate (DCR) provided by enzalutamide in metastatic Castration Resistant Prostate Cancer patients with at least one visceral site involvement.

NCT ID: NCT01939743 Completed - Carcinoma Prostate Clinical Trials

Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate

Start date: October 2011
Phase: Phase 2
Study type: Interventional

Transrectal ultrasound guided biopsy of prostate (TRUS-Bx) is widely used as accepted mode of investigation for prostate cancer in current urology practice. It is considered a minor procedure, which most of the patients tolerate, however 20% of patients refuse to undergo the redo procedure without any analgesia or anesthesia but on the other hand, some authors reveal that 65 to 90% of patients report pain ranging from mild to severe in intensity. Diclofenac is a local and systemic anti-inflammatory drug and it reduces local mediators involved in local pain.The purpose of this study is to find out the role of rectal administration of diclofenac suppositories as an adjunct to 2% xylocaine gel in alleviating intra and post procedural pain in prostatic biopsy with adequately calculated sample size and excluding the patients with contraindication to procedure or diclofenac administration as these were the shortcomings of previous studies.